As per usual instructions
24 hours at 20-25 °C, 7 days at 2-8 °C,
ProBNP may be used as an aid in the diagnosis of patients suspected of having heart failure.
Left ventricular dysfunction can occur as a part of coronary heart disease, arterial hypertension, valvular disease and primary myocardial disease. If the left ventricular dysfunction remains untreated and is progressive, the potential for mortality is high, e.g. due to sudden cardiac death.
Chronic cardiac insufficiency is a clinical syndrome caused by impairment of the cardiac pumping function.
In subjects with left ventricular dysfunction, serum and plasma concentrations of BNP increase, as does the concentration of the putatively inactive amino-terminal fragment, NT-proBNP. ProBNP, comprising 108 amino acids, is secreted mainly by the ventricle and, in this process, is cleaved into physiologically active BNP (77-108) and the N-terminal fragment NT-proBNP (1-76).
Studies indicate that NT-proBNP can be used in diagnostic and prognostic applications. The concentration of NT-proBNP in serum or plasma correlates with the prognosis of the left ventricular dysfunction. Fisher, et al. found that congestive heart failure patients with NT-proBNP values above median had a one year mortality rate of 53% compared to 11% in patients below median. In the GUSTO IV study, which involved more than 6800 patients, it was shown that NT-proBNP was the strongest independent predictor of one-year mortality in patients with acute coronary syndrome. The test is also useful in assigning symptoms to cardiac or non-cardiac causes, and helps to identify subjects with left ventricular dysfunction.
N-Terminal pro brain natriuretic peptide
Please note the new Alere NT-ProBNP assay will be in use from 18/04/2018. This assay is not currently included in our ISO15189:2012 accreditation scope
UK NEQAS for Cardiac Markers
Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018
HTA licence number is 12366
Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235